Assessment of the diagnostic value of T- and B-lymphocyte neogenesis marker (TREC/KREC) identification after hematopoietic stem cell transplantation

Polyakova E.A., Shman T.V., Guryanova I.E., Ignatovich А.S., Kazak V.I., Liubushkin A.V., Belevtsev M.V.

Belarussian research center for pediatric oncology, hematology and immunology, Minsk

Aim: To evaluate methodical validity of T- and B-cell receptor gene recombination product number assessment in patients after hematopoietic stem cell transplantation.

Materials and methods: The DNA of peripheral blood of healthy children (n=98) aged 0.0 (0–15.0) years, who formed a control group, and patients after hematopoietic stem cell transplantation (n=38) aged 7.1 (0.3–15.0) years, was used in the study.

Results and discussion: AUCTREC 0.9554±0.0102 (p<0.001) with diagnostic sensitivity and specificity of 87.38% and 91.84%, respectively, was determined by ROC analysis. AUCKREC was 0.9137±0.02349 (p<0.001). Evaluation of KREC after HSCT allows the method to be used with a diagnostic sensitivity of 85.71% and a specificity of 81.45%.

Conclusion: Identification of T- and B-cell neogenesis markers TREC and KREC is of high diagnostic value in the assessment of immune reconstitution in the post-transplant period in hematopoietic stem cell recipients with congenital defects of the immune system and oncohematological diseases.